Navigation Links
Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
Date:1/7/2009

nificant potential benefits. In particular, ToleroMune should greatly simplify and shorten allergy therapy, while minimizing the risk of the serious and even life-threatening adverse reactions that are associated with current desensitization treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's anti-allergy products offer potential important clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit with changes in the regulatory environment in Europe where authorities are increasingly treating allergen immunotherapies in the same manner as pharmaceuticals, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent products. Circassia is also developing ToleroTrans organ anti-rejection technology, which uses a similar approach to ToleroMune to down-regulate immune responses in transplant patients, and ToleroCare therapy which is designed to dramatically
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Leading ... announce the launch of its new vegan and gluten-free ... extremely effective and provided the results skincare testers were ... create a gentle yet active mask that provided results, ... Louise.” , This Sugar Cane Fruit Mask combines Willow ...
(Date:9/17/2014)... Cadiz Laser Spa offers the ... to clients throughout Central Texas. The newest addition ... Induction Therapy. Using the revolutionary Rejuvapen micro-needling device ... clients correct a wide variety of skin issues. ... Cadiz Laser Spa is currently offering a special ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 17, 2014 ... grant of $50,000 to the National Children’s Oral Health ... and education through NCOHF’s Orange County Oral Health Zone ... Health Zone Program is engaging a range of local ... breaking the cycle of severe tooth decay and its ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... (Pink Sheets: SNDY) is pleased to announce that ... was featured in the "Cover Products" section ... issue. The article focused on the MammoView(TM),s functionality ... in the mammary ducts.The MammoView(TM) product line employs ...
... Together Extensive State/Local Resources and Makes Medical History ... solution for families, consumers and professionals concerned with ... to all New Yorkers. The New York ... www.nycnetworkofcare.org ) is an online clearinghouse that provides ...
... Medicare Reimbursement will have Significant Impact on the ... Mass., Feb. 19 Millennium Research Group (MRG) ... for Urological Devices 2008 report to reflect ... Due mainly to a favorable upgrade in Medicare ...
... Top 100 Has Placed McLaren In Top 25 Nationwide Since ... The SDI Top 100, an annual list that ranks the ... has ranked Flint-based McLaren Health Care the top-rated health system ... the nation, placing it 16th on this year,s list.McLaren has ...
... - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) ... the fourth quarter ending December 31, 2008 and full year ... specified otherwise, all amounts are in U.S. dollars and in ... for us as we concluded a series of corporate development ...
... Fla., Feb. 19 Smith & Nephew,s Advanced Wound ... announced that the United States Patent and Trademark Office ... negative pressure wound therapy (NPWT) patents during re-examination of ... Patent Office found that prior art showed that almost ...
Cached Medicine News:Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 3Health News:Intermittent Catheter Market to Surpass 40% CAGR Between 2008 and 2012 2Health News:National Health Care List Ranks McLaren Health Care Top in Michigan; 16th in Nation 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19Health News:United States Patent Office Rejects KCI's Patents 2Health News:United States Patent Office Rejects KCI's Patents 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: